Skip to main content
. 2017 May 19;8(34):57782–57799. doi: 10.18632/oncotarget.17997

Figure 1. Proposed molecular mechanism of VK2 in prostate cancer.

Figure 1

VK2 targets HDGF protein during the development of carcinogenesis and targets androgen receptors (AR), Akt and NF-kB during the progression of PCa.